AusPAR Attachment 1: Product Information for Silodosin
The responder rate (i.e. improvement in the IPSS total score by at least 25 %) was significantly higher in the silodosin (68 %) and tamsulosin group (65 %), as compared to placebo (53 %). In the long-term open-label extension phase of these controlled studies, in which patients received silodosin for up to 1 year, the symptom improvement ... ................
................
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- watershed information for kids
- new product ideas for students
- health information for senior citizens
- background information for science projects
- heart health information for seniors
- nutritional information for starbucks
- reverse mortgage information for dummies
- medical information for seniors
- 1 product website
- product information sheet sample
- product information sheet template
- product information sheet template free